Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Butalbital is a short-to-intermediate acting barbiturate used primarily for the symptomatic treatment of tension-type (muscle contraction) headaches. It is most commonly administered in combination with other agents such as acetaminophen or aspirin and caffeine. Butalbital acts as a central nervous system depressant by binding to a distinct site on the Gamma-aminobutyric acid type A receptor (GABAA receptor) complex, increasing chloride ion influx and enhancing inhibitory neurotransmission. This results in sedative, muscle-relaxing, and anxiolytic effects that help relieve headache symptoms. Butalbital has a narrow therapeutic index and can be habit-forming; it is not indicated for migraine headaches due to lack of evidence for efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on butalbital.